BDBM282832 6-(4-(3-chloro-4-fluorophenyl)-1-((cis)-3- hydroxycyclobutyl)-1H-imidazol-5-yl)imidazo[1,2- b]pyridazine-3-carbonitrile::US10287295, Example 39'::US9884868, Example 39'

SMILES: O[C@H]1C[C@H](C1)n1cnc(c1-c1ccc2ncc(C#N)n2n1)-c1ccc(F)c(Cl)c1

InChI Key: InChIKey=OJNNUDOOADABHK-XBXGTLAGSA-N

Data: 4 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 282832   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
TGF-beta receptor type-1 (Homo sapiens (Human))	BDBM282832 (6-(4-(3-chloro-4-fluorophenyl)-1-((cis)-3- hydroxy...) Show SMILES O[C@H]1C[C@H](C1)n1cnc(c1-c1ccc2ncc(C#N)n2n1)-c1ccc(F)c(Cl)c1 |r,wU:3.5,1.0,(-2.83,-5.84,;-1.74,-4.75,;-1.74,-3.21,;-.2,-3.21,;-.2,-4.75,;.88,-2.12,;2.35,-2.6,;3.25,-1.35,;2.35,-.11,;.88,-.58,;-.45,.19,;-.45,1.73,;-1.78,2.5,;-3.12,1.73,;-4.58,2.2,;-5.49,.96,;-4.58,-.29,;-5.06,-1.75,;-5.53,-3.22,;-3.12,.19,;-1.78,-.58,;2.75,1.38,;1.66,2.47,;2.06,3.96,;3.54,4.35,;3.94,5.84,;4.63,3.27,;6.12,3.66,;4.24,1.78,)| Show InChI InChI=1S/C20H14ClFN6O/c21-15-5-11(1-2-16(15)22)19-20(27(10-25-19)12-6-14(29)7-12)17-3-4-18-24-9-13(8-23)28(18)26-17/h1-5,9-10,12,14,29H,6-7H2/t12-,14+	PDB MMDB UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.900	n/a	n/a	n/a	n/a	7.4	25
Rigel Pharmaceuticals, Inc.; Bristol-Myers Squibb Company US Patent					Assay Description Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...				US Patent US9884868 (2018) BindingDB Entry DOI: 10.7270/Q20P122M
					More data for this Ligand-Target Pair
TGF-beta receptor type II (Homo sapiens (Human))	BDBM282832 (6-(4-(3-chloro-4-fluorophenyl)-1-((cis)-3- hydroxy...) Show SMILES O[C@H]1C[C@H](C1)n1cnc(c1-c1ccc2ncc(C#N)n2n1)-c1ccc(F)c(Cl)c1 |r,wU:3.5,1.0,(-2.83,-5.84,;-1.74,-4.75,;-1.74,-3.21,;-.2,-3.21,;-.2,-4.75,;.88,-2.12,;2.35,-2.6,;3.25,-1.35,;2.35,-.11,;.88,-.58,;-.45,.19,;-.45,1.73,;-1.78,2.5,;-3.12,1.73,;-4.58,2.2,;-5.49,.96,;-4.58,-.29,;-5.06,-1.75,;-5.53,-3.22,;-3.12,.19,;-1.78,-.58,;2.75,1.38,;1.66,2.47,;2.06,3.96,;3.54,4.35,;3.94,5.84,;4.63,3.27,;6.12,3.66,;4.24,1.78,)| Show InChI InChI=1S/C20H14ClFN6O/c21-15-5-11(1-2-16(15)22)19-20(27(10-25-19)12-6-14(29)7-12)17-3-4-18-24-9-13(8-23)28(18)26-17/h1-5,9-10,12,14,29H,6-7H2/t12-,14+	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	4.47E+3	n/a	n/a	n/a	n/a	n/a	n/a
University of Wisconsin at Madison					Assay Description Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...				J Med Chem 51: 7243-52 (2008) BindingDB Entry DOI: 10.7270/Q2B85BFB
					More data for this Ligand-Target Pair
TGF-betaR1 T204D (Homo sapiens (Human))	BDBM282832 (6-(4-(3-chloro-4-fluorophenyl)-1-((cis)-3- hydroxy...) Show SMILES O[C@H]1C[C@H](C1)n1cnc(c1-c1ccc2ncc(C#N)n2n1)-c1ccc(F)c(Cl)c1 |r,wU:3.5,1.0,(-2.83,-5.84,;-1.74,-4.75,;-1.74,-3.21,;-.2,-3.21,;-.2,-4.75,;.88,-2.12,;2.35,-2.6,;3.25,-1.35,;2.35,-.11,;.88,-.58,;-.45,.19,;-.45,1.73,;-1.78,2.5,;-3.12,1.73,;-4.58,2.2,;-5.49,.96,;-4.58,-.29,;-5.06,-1.75,;-5.53,-3.22,;-3.12,.19,;-1.78,-.58,;2.75,1.38,;1.66,2.47,;2.06,3.96,;3.54,4.35,;3.94,5.84,;4.63,3.27,;6.12,3.66,;4.24,1.78,)| Show InChI InChI=1S/C20H14ClFN6O/c21-15-5-11(1-2-16(15)22)19-20(27(10-25-19)12-6-14(29)7-12)17-3-4-18-24-9-13(8-23)28(18)26-17/h1-5,9-10,12,14,29H,6-7H2/t12-,14+	PDB MMDB NCI pathway Reactome pathway KEGG B.MOAD DrugBank GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.900	n/a	n/a	n/a	n/a	n/a	n/a
University of Wisconsin at Madison					Assay Description Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...				J Med Chem 51: 7243-52 (2008) BindingDB Entry DOI: 10.7270/Q2B85BFB
					More data for this Ligand-Target Pair
TGF-beta receptor type II (Homo sapiens (Human))	BDBM282832 (6-(4-(3-chloro-4-fluorophenyl)-1-((cis)-3- hydroxy...) Show SMILES O[C@H]1C[C@H](C1)n1cnc(c1-c1ccc2ncc(C#N)n2n1)-c1ccc(F)c(Cl)c1 |r,wU:3.5,1.0,(-2.83,-5.84,;-1.74,-4.75,;-1.74,-3.21,;-.2,-3.21,;-.2,-4.75,;.88,-2.12,;2.35,-2.6,;3.25,-1.35,;2.35,-.11,;.88,-.58,;-.45,.19,;-.45,1.73,;-1.78,2.5,;-3.12,1.73,;-4.58,2.2,;-5.49,.96,;-4.58,-.29,;-5.06,-1.75,;-5.53,-3.22,;-3.12,.19,;-1.78,-.58,;2.75,1.38,;1.66,2.47,;2.06,3.96,;3.54,4.35,;3.94,5.84,;4.63,3.27,;6.12,3.66,;4.24,1.78,)| Show InChI InChI=1S/C20H14ClFN6O/c21-15-5-11(1-2-16(15)22)19-20(27(10-25-19)12-6-14(29)7-12)17-3-4-18-24-9-13(8-23)28(18)26-17/h1-5,9-10,12,14,29H,6-7H2/t12-,14+	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	4.47E+3	n/a	n/a	n/a	n/a	n/a	n/a
Rigel Pharmaceuticals, Inc.; Bristol-Myers Squibb Company US Patent									US Patent US9884868 (2018) BindingDB Entry DOI: 10.7270/Q20P122M
					More data for this Ligand-Target Pair